ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference
October 03 2023 - 8:30AM
Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a
biotech/agtech R&D company engaged in the development of
therapeutic, medicinal and nutritional product candidates derived
from proprietary algal cultures, announces that management will
deliver a company presentation and will hold investor meetings at
the 8th Annual Dawson James Small Cap Growth Conference being held
Thursday, October 12, 2023 at the Wyndham Grand Jupiter at
Harbourside Place in Jupiter, Fla.
Event: |
8th Annual Dawson James Small Cap Growth Conference |
Date: |
Thursday, October 12, 2023 |
Time: |
9:00 a.m. Eastern Time |
Location: |
Wyndham Grand Jupiter at Harbourside Place |
Webcast: |
https://wsw.com/webcast/dawson8/zivo/2075040 |
Investors interested in arranging a meeting with
ZIVO management should contact Tirth Patel at LHA Investor
Relations at tpatel@lhai.com.
About ZIVO Bioscience
ZIVO Bioscience is a research and development
company with an intellectual property portfolio comprised of
proprietary algal and bacterial strains, biologically active
molecules and complexes, production techniques, cultivation
techniques and patented or patent pending inventions for
applications in human and animal health. Please visit
www.zivobioscience.com for more information.
Forward Looking Statements
Except for any historical information, the
matters discussed in this press release contain forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
including with respect to the Company’s product candidate’s
potential to generate revenues and the expected time frame for
results of future studies. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates" and similar
expressions or variations of such words are intended to identify
forward-looking statements. Although ZIVO believes that we have a
reasonable basis for each forward-looking statement, we caution you
that these statements are based on a combination of facts and
factors currently known by us and our expectations of the future,
about which we cannot be certain. Our actual future results may be
materially different from what we expect due to factors largely
outside our control, including risks that our strategic
partnerships may not facilitate the commercialization or market
acceptance of our products; risks that we will be unable to
increase production sufficient to meet our expected demand; risks
that our products may not be ready for commercialization in a
timely manner or at all; risks that our products will not
perform as expected based on results of our pre-clinical and
clinical trials; our ability to raise additional funds;
uncertainties inherent in the development process of our products;
changes in regulatory requirements or decisions of regulatory
authorities; the size and growth potential of the markets for our
products; the results of clinical trials, our ability to protect
our intellectual property rights and other risks, uncertainties and
assumptions, including those described under the heading “Risk
Factors” in our filings with the Securities and Exchange
Commission. These forward–looking statements speak only as of the
date of this press release and ZIVO undertakes no obligation to
revise or update any forward–looking statements for any reason,
even if new information becomes available in the future.
Contacts:
ZIVO BioscienceKeith Marchiando, Chief
Financial Officer (248) 452-9866 x130
kmarchiando@zivobioscience.com
LHA Investor Relations Tirth T. Patel
(212) 201-6614 tpatel@lhai.com
Zivo Bioscience (NASDAQ:ZIVOW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zivo Bioscience (NASDAQ:ZIVOW)
Historical Stock Chart
From Jul 2023 to Jul 2024